You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Relvar for controlled patients

Relvar isn’t just an effective choice for patients who are uncontrolled on their current asthma treatment – it can be a great choice for controlled asthma patients too.

woman staring

Sara is a patient whose asthma is currently controlled on an ICS/LABA MART regimen. However, because MART regimens rely on patient perceptions to control symptoms, which can be unreliable,1 underlying inflammation may still be present.

In fact, fewer than 1 out of 5 patients remain well controlled at 1 year with budesonide/formoterol MART therapy,1 suggesting the underlying issue may remain unresolved.

Relvar may be able to help.

women doing yoga while beast is trapped
women doing yoga while beast is trapped

Fluticasone furoate and vilanterol are not licensed as monotherapies in asthma in all markets.
Hypothetical patient used for illustrative purposes only.

Sara remains well controlled with added benefits of controlling her underlying inflammation and a simple once-daily dosing regimen2,4

The invisible symptoms of asthma

What are the underlying symptoms of asthma that MART regimens may not be addressing?


Discover Relvar


*In vitro data: clinical relevance is uncertain.


ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; MART, maintenance and reliever therapy.

  1. Chapman KR, et al. Thorax 2010;65:747–752.
  2. Bardsley G, et al. Respir Res 2018;19:133.
  3. Daley-Yates P, et al. Br J Clin Pharmacol 2020;1–11.
  4. Global Datasheet Fluticasone furoate/vilanterol: v11, March 2020.

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

PM-IE-FFV-WCNT-230007 June 2023